Pilot Study on the Effectiveness of Novel Peripherally Inserted Central Catheter (PICC) Securement Dressing in Preventing PICC Dislodgement
8 september 2026 bijgewerkt door: Changi General Hospital
Evidence regarding clinical effectiveness and acceptability of PICC sleeves remain limited.
Few randomised controlled trials have evaluated PICC sleeves in routine hospital practice, and there is limited evidence regarding their feasibility, safety and influence on line condition.
This pilot randomised controlled trial aims to evaluate the feasibility, safety, and user experience of a protective PICC sleeve among hospitalised patients with PICCs.
Studie Overzicht
Toestand
Voltooid
Conditie
Interventie / Behandeling
Studietype
Ingrijpend
Inschrijving (Werkelijk)
67
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
-
Singapore, Singapore, 529889
- Changi General Hospital
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Nee
Beschrijving
Inclusion Criteria:
- Adult patients receiving PICC placement for various medical conditions
Exclusion Criteria:
- Patients with known allergies to materials in the PICC sleeve
- Patients contraindicated for PICC placement
- Patients who are aggressive and/or restless
- Patients whose skin condition is unsuitable for CHG gel dressing application (e.g. skin with eczema plaques, bullous pemphigoid)
- Patients who have no mental capacity to give consent
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Geen tussenkomst: The control group
The control group used the standard securement dressing
|
|
|
Experimenteel: The Treatment group
The treatment group received appropriately sized PICC sleeve cover in addition to standard device securement practices.
|
The novel PICC sleeve cover would be applied on the intervention group in addition to standard PICC securement practices.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Participant Recruitment Rate
Tijdsspanne: 16 months
|
Number of participants recruited over the recruitment period
|
16 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Intervention Adherence
Tijdsspanne: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Percentage of participants who were compliant to wearing the PICC sleeve cover
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Retention of Study Participants across 3 Time-points
Tijdsspanne: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Number of study participants across 3 time-points (2 days after PICC insertion, 14 days after PICC insertion or upon removal, whichever earlier, and 7 days after discharge from hospital) presented as a percentage of the original number of study participants in each arm
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Completeness of Data Collected
Tijdsspanne: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Percentage of data collected over the ideal number of data to be collected
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Number of Adverse Events
Tijdsspanne: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Percentage of participants suffering from adverse events over the total number of participants
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Patient-Reported Dislodgement Risk
Tijdsspanne: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Mean score of all participants rating their perceived dislodgement risk on a self-designed questionnaire from 1 (strongly disagree) to 5 (strongly agree) in each study arm.
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Patient-Reported Comfort Level
Tijdsspanne: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Mean score of all participants rating their perceived comfort level on a self-designed questionnaire from 1 (strongly disagree) to 5 (strongly agree) in each study arm.
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Patient-Reported Visibility Level
Tijdsspanne: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Mean score of all participants rating their perceived visibility level on a self-designed questionnaire from 1 (strongly disagree) to 5 (strongly agree) in each study arm.
The visibility level refers to the degree the PICC dressing is exposed to the onlookers and how that may affect their own self-image.
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Patient-Reported User-friendliness
Tijdsspanne: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Mean score of all participants rating their perceived user-friendliness of the PICC dressing on a self-designed questionnaire from 1 (strongly disagree) to 5 (strongly agree) in each study arm.
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Patient-Reported Acceptability Outcome
Tijdsspanne: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
The mean of the mean scores for patient-reported dislodgement risk, comfort level, visibility level and user-friendliness.
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Staff-Reported Dislodgement Risk
Tijdsspanne: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Mean score of all participants rating their patients' perceived dislodgement risk on a self-designed questionnaire from 1 (strongly disagree) to 5 (strongly agree) in each study arm.
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Staff-Reported Comfort Level
Tijdsspanne: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Mean score of all participants rating their patients' perceived comfort level on a self-designed questionnaire from 1 (strongly disagree) to 5 (strongly agree) in each study arm.
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Staff-Reported Visibility Level
Tijdsspanne: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Mean score of all participants rating their patient's perceived visibility level on a self-designed questionnaire from 1 (strongly disagree) to 5 (strongly agree) in each study arm.
The visibility level refers to the degree the PICC dressing is exposed to the onlookers and how that may affect their own self-image.
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Staff-Reported User-friendliness
Tijdsspanne: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Mean score of all participants rating their patient's perceived user-friendliness of the PICC dressing on a self-designed questionnaire from 1 (strongly disagree) to 5 (strongly agree) in each study arm.
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Staff-Reported Acceptability Outcome
Tijdsspanne: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
The mean of the mean scores for staff-reported dislodgement risk, comfort level, visibility level and user-friendliness.
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of Dislodgement Cases
Tijdsspanne: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Number of dislodgement cases (complete/partial)
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Dressing Condition
Tijdsspanne: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Percentage of participants with intact dressing or dressing with some peeling over the total number of participants in each arm.
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
CHG Gel Condition
Tijdsspanne: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Percentage of participants with intact CHG gel or CHG gel with some swelling over the total number of participants in each arm.
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
External Length
Tijdsspanne: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Percentage of participants with the same or minimally changed (< 2cm) external length of PICC over the total number of participants in each arm.
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Patency of PICC Lumens
Tijdsspanne: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Percentage of participants whose PICC are still patent with or without backflow over the total number of participants in each arm
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Insertion Site
Tijdsspanne: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Percentage of participants without any redness, slough or necrotic tissue at the insertion site over the total number of participants in each arm
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Discharge from PICC insertion site
Tijdsspanne: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Percentage of participants with no discharge from the PICC insertion site over the total number of participants in each arm
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Surrounding Skin around PICC Insertion Site
Tijdsspanne: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Percentage of participants with nil redness of surrounding skin around the PICC insertion site over the total number of participants in each arm
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Algemene publicaties
- Chan RJ, Northfield S, Larsen E, Mihala G, Ullman A, Hancock P, Marsh N, Gavin N, Wyld D, Allworth A, Russell E, Choudhury MA, Flynn J, Rickard CM. Central venous Access device SeCurement And Dressing Effectiveness for peripherally inserted central catheters in adult acute hospital patients (CASCADE): a pilot randomised controlled trial. Trials. 2017 Oct 4;18(1):458. doi: 10.1186/s13063-017-2207-x.
- O'Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, Lipsett PA, Masur H, Mermel LA, Pearson ML, Raad II, Randolph AG, Rupp ME, Saint S; Healthcare Infection Control Practices Advisory Committee (HICPAC) (Appendix 1). Summary of recommendations: Guidelines for the Prevention of Intravascular Catheter-related Infections. Clin Infect Dis. 2011 May;52(9):1087-99. doi: 10.1093/cid/cir138. No abstract available.
- Karpanen T, Casey A, Whitehouse T, Nightingale P, Das I, Elliott TS. Abstracts from the 3rd International Conference on Prevention and Infection Control (ICPIC 2015). Antimicrob Resist Infect Control. 2015 Jun 16;4 Suppl 1(Suppl 1):I1-P308. doi: 10.1186/2047-2994-4-s1-i1. No abstract available.
- Dong H, Zhu Y, Zhang X, Yin X, Liu F. Chest CT tomography vs. intracavitary electrocardiogram guidance in predicting the length of PICC placement. BMC Surg. 2022 May 19;22(1):197. doi: 10.1186/s12893-022-01604-0.
- Grau D, Clarivet B, Lotthe A, Bommart S, Parer S. Complications with peripherally inserted central catheters (PICCs) used in hospitalized patients and outpatients: a prospective cohort study. Antimicrob Resist Infect Control. 2017 Jan 28;6:18. doi: 10.1186/s13756-016-0161-0. eCollection 2017.
- Moureau N, Lamperti M, Kelly LJ, Dawson R, Elbarbary M, van Boxtel AJ, Pittiruti M. Evidence-based consensus on the insertion of central venous access devices: definition of minimal requirements for training. Br J Anaesth. 2013 Mar;110(3):347-56. doi: 10.1093/bja/aes499. Epub 2013 Jan 29.
- Yu K, Li J, Zhang D, Liu B, Wang K, Liu W, Shi Y, Zhao Y, Liu Y, Guo N, Sun W. Types of peripherally inserted central catheters and the risk of unplanned removals in patients: A prospective cohort study. Int J Nurs Stud. 2024 Jan;149:104621. doi: 10.1016/j.ijnurstu.2023.104621. Epub 2023 Oct 12.
- Xu B, Zhang J, Hou J, Ma M, Gong Z, Tang S. Nurses' Attitudes and Knowledge of Peripherally Inserted Central Catheter Maintenance in Primary Hospitals in China: A Cross-Sectional Survey. Risk Manag Healthc Policy. 2020 Jul 28;13:903-913. doi: 10.2147/RMHP.S250741. eCollection 2020.
- Rickard CM, Marsh NM, Webster J, Gavin NC, Chan RJ, McCarthy AL, Mollee P, Ullman AJ, Kleidon T, Chopra V, Zhang L, McGrail MR, Larsen E, Choudhury MA, Keogh S, Alexandrou E, McMillan DJ, Mervin MC, Paterson DL, Cooke M, Ray-Barruel G, Castillo MI, Hallahan A, Corley A, Geoffrey Playford E. Peripherally InSerted CEntral catheter dressing and securement in patients with cancer: the PISCES trial. Protocol for a 2x2 factorial, superiority randomised controlled trial. BMJ Open. 2017 Jun 15;7(6):e015291. doi: 10.1136/bmjopen-2016-015291.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
21 maart 2024
Primaire voltooiing (Werkelijk)
10 juli 2025
Studie voltooiing (Werkelijk)
25 september 2025
Studieregistratiedata
Eerst ingediend
2 september 2026
Eerst ingediend dat voldeed aan de QC-criteria
8 september 2026
Eerst geplaatst (Werkelijk)
14 september 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
14 september 2026
Laatste update ingediend die voldeed aan QC-criteria
8 september 2026
Laatst geverifieerd
1 september 2025
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- 2024-2117
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Beschrijving IPD-plan
Legal/Regulatory: Data protection laws, consent limitations, institutional policies
Commercial: Proprietary concerns, competitive advantage, patent issues
Ethical: Privacy concerns, insufficient original consent, ethics approval scope
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .